Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (281-290 of 499) with videos related to

Pageof 50
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 4, 2007
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment GroupBernard Nordlinger, Eric Van Cutsem, Philippe Rougier, et al.
Future Oncology (London, England)|June 11, 2024
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summaryKohei Shitara, Manish A Shah, Florian Lordick, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2022
Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD databaseJan Franko, Jun Yin, Richard A Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancerJosep Tabernero, Eric Van Cutsem, Eduardo Díaz-Rubio, et al.
Clinical Colorectal Cancer|July 29, 2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancerBert H O'Neil, Calin Cainap, Eric Van Cutsem, et al.
ESMO Open|May 2, 2018
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data setAxel Grothey, Takayuki Yoshino, Gyorgy Bodoky, et al.
Future Oncology (London, England)|November 10, 2020
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST studyEric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, et al.
Investigational New Drugs|March 7, 2018
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studiesHerbert Hurwitz, Eric Van Cutsem, Johanna Bendell, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 5, 2016
Treatment sequence of synchronously (liver) metastasized colon cancerThomas Gruenberger, Geerard Beets, Jean-Luc Van Laethem, et al.
Pageof 50

Showing results (281-290 of 499) with videos related to

Sort By:
Pageof 50
European Journal of Cancer (Oxford, England : 1990)|September 4, 2007
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment GroupBernard Nordlinger, Eric Van Cutsem, Philippe Rougier, et al.
Future Oncology (London, England)|June 11, 2024
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summaryKohei Shitara, Manish A Shah, Florian Lordick, et al.
European Journal of Cancer (Oxford, England : 1990)|August 22, 2022
Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD databaseJan Franko, Jun Yin, Richard A Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancerJosep Tabernero, Eric Van Cutsem, Eduardo Díaz-Rubio, et al.
Clinical Colorectal Cancer|July 29, 2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancerBert H O'Neil, Calin Cainap, Eric Van Cutsem, et al.
ESMO Open|May 2, 2018
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data setAxel Grothey, Takayuki Yoshino, Gyorgy Bodoky, et al.
Future Oncology (London, England)|November 10, 2020
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST studyEric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, et al.
Investigational New Drugs|March 7, 2018
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studiesHerbert Hurwitz, Eric Van Cutsem, Johanna Bendell, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 5, 2016
Treatment sequence of synchronously (liver) metastasized colon cancerThomas Gruenberger, Geerard Beets, Jean-Luc Van Laethem, et al.
Pageof 50